NeuroStar Publication in JAACAP Open Shows Efficacy in Depressed Adolescents
Real-world data from the NeuroStar TrakStar Clinical Database, the largest repository of its kind for depression outcomes, reveals promising...
Sandoz to Acquire Just-Evotec Biologics in Toulouse
Sandoz’s proposed acquisition of Just-Evotec Biologics (JEB) for approximately $300 million marks a significant move to solidify its position...
Cardiff Oncology Announces Positive Phase 2 Trial Data in mCRC
Cardiff Oncology Reports Promising Phase 2 Onvansertib Data in RAS-Mutated Metastatic Colorectal Cancer Cardiff Oncology has unveiled positive interim...
Cardiff Oncology Q2 2025 Results: Business Update
Cardiff Oncology, a clinical-stage biotech focusing on PLK1 inhibition in cancer treatment, recently completed enrollment in its crucial Phase...
AscellaHealth and Abeona Partner to Provide Cell-Based Gene Therapy for Rare Disease
AscellaHealth’s partnership with Abeona Therapeutics in the successful commercialization of Zevaskyn™, a groundbreaking gene therapy for recessive dystrophic epidermolysis...
NewGen Expands US Presence with Cytometry Tech Acquisition
NewGenIVF Group’s acquisition of cytometry technology and assets, including 18 cell-sorting systems and related patents, marks a decisive move...
Calidi’s Stem-Cell Sarcoma Therapy Gets FDA Fast Track
Calidi Biotherapeutics has secured FDA Fast Track designation for CLD-201 (Supernova), its allogeneic adipose stem-cell-loaded oncolytic virus for treating...
Cognition Therapeutics Shows Zervimesine’s Impact on Dementia and Alzheimer’s
Cognition Therapeutics Presents Promising Zervimesine Data at AAIC 2025, Highlighting Potential in Dementia with Lewy Bodies and Alzheimer’s Disease...
Novo Nordisk Lowers 2025 Sales and Profit Outlook
Novo Nordisk has revised its 2025 sales and operating profit growth outlook downwards, now projecting 8-14% and 10-16% growth...
Duravyu™ Phase 3 Trials for Wet AMD Conclude Enrollment
EyePoint Pharmaceuticals has completed enrollment in its Phase 3 LUCIA trial for Duravyu, a sustained-release tyrosine kinase inhibitor (TKI)...